Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Medical Oncology, START Madrid-FJD, Early Phase Clinical Trials Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Drugs Today (Barc). 2021 Mar;57(3):187-197. doi: 10.1358/dot.2021.57.3.3233363.
The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lung cancer or melanoma. The preliminary results, particularly in endometrial cancer, show a high affinity against PD-1 with encouraging clinical activity. Here we summarize the development of this compound as well as the current preclinical and clinical data and potential future development.
针对程序性细胞死亡蛋白 1（PD-1）及其配体程序性细胞死亡 1 配体 1（PD-L1）的单克隆抗体的使用已广泛扩展到许多肿瘤，如黑色素瘤、非小细胞肺癌、肾或淋巴瘤等。其中一些已被批准作为一线或二线治疗药物，如 pembrolizumab、nivolumab 或 cemiplimab。Dostarlimab 是一种研究性的人源化抗 PD-1 单克隆抗体，目前正在进行单药和联合治疗的研究，用于妇科肿瘤，也用于肺癌或黑色素瘤。初步结果，特别是在子宫内膜癌中，显示出对 PD-1 的高亲和力和令人鼓舞的临床活性。在这里，我们总结了该化合物的开发情况以及目前的临床前和临床数据以及潜在的未来发展。
